Advice
Following a full submission.
Miglustat is accepted for use within NHS Scotland for the treatment of mild to moderate type 1 Gaucher disease in patients for whom enzyme replacement therapy is unsuitable.
Miglustat should only be initiated by physicians experienced in the management of Gaucher’s disease.
Download detailed advice26KB (PDF)
Medicine details
- Medicine name:
- Miglustat (Zavesca®)
- SMC ID:
- 133/04
- Indication:
- Moderate type 1 Gaucher disease
- Pharmaceutical company
- Actelion Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 December 2004